An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of Octaplas in the Management of Pediatric Patients Who Require Replacement of Multiple Coagulation Factors.
Phase of Trial: Phase IV
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Plasma (Primary)
- Indications Blood coagulation disorders
- Focus Adverse reactions
- Sponsors Octapharma
- 13 Apr 2018 Status changed from active, no longer recruiting to completed.
- 28 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
- 28 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.